Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Enrolling By Invitation NCT07833046

Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection

Conditions: Multiple Myeloma

Sex: All
Healthy volunteers: No
Enrollment: 40
Sponsor: RenJi Hospital

Location: Renji Hospital, Shanghai Jiaotong University School of Medicine Shanghai Shanghai Municipality

Summary

This is an open-label, multicenter, observational study (non-interventional study) to evaluate the long-term safety, efficacy, and in vivo pharmacokinetic persistence of CAR-T cells in subjects treated with GC012F Injection

Eligibility Criteria

Inclusion Criteria: * Patients with multiple myeloma who previously received GC012F Injection infusion in an investigator-initiated trial; * Patients who have completed the safety and efficacy follow-up of the main study or withdrawn early; * Patients who agree to sign the informed consent form and are willing and able to comply with the visits, laboratory tests, and other protocol requirements specified in the study visit schedule; Exclusion Criteria: * Patients with multiple myeloma who participated in the main study but withdrew early without receiving GC012F Injection; * Patients who refuse to undergo long-term follow-up after GC012F Injection treatment;

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07833046). StuddyBuddy aggregates publicly available trial information.